NEW
Stock Screener with Intrinsic Value
Novo Nordisk A/S (NVO)
Last Price$86.30.8%
Market Cap$384.7B
LTM EPS
DKK 21.3
-22.4% YOY growth
NTM EPS
DKK 26.7
+25.7% YOY growth
Current P/E
29.7x LTM
22.8x NTM
52w high P/E
51.2x LTM
43.7x NTM
52w low P/E
28.4x LTM
17.6x NTM
10Y avg P/E
28.4x LTM
10.4x NTM
NVO Peter Lynch Chart
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Explore more intrinsic value tools hub for NVO
Earnings growth model
Peter Lynch Fair Value
Earnings Power Value
Discount rate
Ben Graham Fair Value
Reverse DCF
Relative Value
Intrinsic Value
DCF value calculator
Margin of safety
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Novo Nordisk A/S earnings per share (EPS)?
Novo Nordisk A/S earnings per share (EPS) for the twelve months ending Jan 10, 2025 was DKK 21.3, a (22.4%) increase year-over-year.
What is Novo Nordisk A/S Price to Earnings (P/E) ratio?
As of Jan 10, 2025, Novo Nordisk A/S's P/E ratio is 29.7x. This is calculated by dividing the current share price of $86.3 by the Earnings per Share (EPS) for the trailing twelve months, which is DKK 21.3. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Is Novo Nordisk A/S overvalued or undervalued?
Novo Nordisk A/S is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $65.9, compared to a market price of around $86.3. This suggests a potential overvaluation of 23.7%.